Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
about
Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureMetabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusEffectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Canagliflozin: A Review in Type 2 Diabetes.Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus.Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.SGLT2 inhibitors: the latest "new kids on the block"!Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to dateSodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
P2860
Q26767263-A3049886-4605-41D1-AFB4-94D9CD1093A3Q28080114-ED9D4191-33B1-4B4B-9AB1-D0B7CE4D0EA6Q33871321-AE7439CB-3FF1-456A-B7ED-23A9612BBE22Q33882438-3C5F07AA-028A-4873-958C-14E0C1D5763EQ37097189-87295066-77CF-412A-92A5-AA8856580664Q37588847-5193DCF4-BE24-471E-ADB0-FADA8104B1EEQ37632127-0C9850C0-1104-4934-BF12-001659CAD97CQ38429845-8E04A7E0-148F-4068-A07C-6DFEA407DE7EQ38663903-86325921-468F-4959-A2B9-8F79859A3F70Q38783203-1898B9FC-FB74-43A2-A916-048EC98FC3E8Q38960765-29C5B590-A589-4DB4-A811-4293C749C011Q39300071-E2D100B0-B699-4AAB-9F34-62E7E3AA31C5Q40081685-44752D72-D013-4D0F-BDF9-23BD67F141B7Q40758518-6190F0B9-296A-4D2D-A327-853D6E726C55Q41507487-A4019596-5061-4611-8EA7-939905D9A72EQ42360591-88ABB269-EB17-4ECC-820E-60D14C1B5A98Q42373168-B3BB33D9-4769-4151-AA7C-0101AA7BE92AQ47115045-6F798917-E30A-4BD1-9916-258370FDF58FQ51565743-02BB79F3-1FDA-4DBB-A1D1-16F98B5527B5
P2860
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Blood pressure reduction: an a ...... patients with type 2 diabetes.
@en
type
label
Blood pressure reduction: an a ...... patients with type 2 diabetes.
@en
prefLabel
Blood pressure reduction: an a ...... patients with type 2 diabetes.
@en
P2860
P356
P1433
P1476
Blood pressure reduction: an a ...... patients with type 2 diabetes.
@en
P2093
Colleen Majewski
George L Bakris
P2860
P304
P356
10.2337/DC14-1596
P407
P577
2015-03-01T00:00:00Z